KR102418167B1 - 중추 신경계 장애의 치료에서의 2,4-티아졸리딘디온 유도체 - Google Patents

중추 신경계 장애의 치료에서의 2,4-티아졸리딘디온 유도체 Download PDF

Info

Publication number
KR102418167B1
KR102418167B1 KR1020167030649A KR20167030649A KR102418167B1 KR 102418167 B1 KR102418167 B1 KR 102418167B1 KR 1020167030649 A KR1020167030649 A KR 1020167030649A KR 20167030649 A KR20167030649 A KR 20167030649A KR 102418167 B1 KR102418167 B1 KR 102418167B1
Authority
KR
South Korea
Prior art keywords
compound
composition
disease
delete delete
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167030649A
Other languages
English (en)
Korean (ko)
Other versions
KR20160145639A (ko
Inventor
콜라조 아나 마리아 가르시아
데이비드 존 어거스터스 에클랜드
라란자 마리아 필라 피즈퀘타
페데몬테 마르크 마르티넬
Original Assignee
미노릭스 테라퓨틱스 에스.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미노릭스 테라퓨틱스 에스.엘. filed Critical 미노릭스 테라퓨틱스 에스.엘.
Publication of KR20160145639A publication Critical patent/KR20160145639A/ko
Application granted granted Critical
Publication of KR102418167B1 publication Critical patent/KR102418167B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167030649A 2014-04-02 2015-04-01 중추 신경계 장애의 치료에서의 2,4-티아졸리딘디온 유도체 Active KR102418167B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382130 2014-04-02
EP14382130.4 2014-04-02
PCT/EP2015/057224 WO2015150476A1 (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Publications (2)

Publication Number Publication Date
KR20160145639A KR20160145639A (ko) 2016-12-20
KR102418167B1 true KR102418167B1 (ko) 2022-07-08

Family

ID=50513194

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167030649A Active KR102418167B1 (ko) 2014-04-02 2015-04-01 중추 신경계 장애의 치료에서의 2,4-티아졸리딘디온 유도체

Country Status (24)

Country Link
US (3) US9782395B2 (enExample)
EP (2) EP3125888B1 (enExample)
JP (2) JP6745726B2 (enExample)
KR (1) KR102418167B1 (enExample)
CN (1) CN106470991B (enExample)
AU (1) AU2015239112C1 (enExample)
CA (1) CA2943373C (enExample)
CL (1) CL2016002508A1 (enExample)
CY (2) CY1120454T1 (enExample)
DK (2) DK3388064T3 (enExample)
EA (2) EA202091120A3 (enExample)
ES (2) ES2678046T3 (enExample)
HR (2) HRP20180983T1 (enExample)
HU (2) HUE055351T2 (enExample)
IL (1) IL248037B (enExample)
LT (2) LT3388064T (enExample)
MX (1) MX373234B (enExample)
NZ (1) NZ725492A (enExample)
PL (2) PL3388064T3 (enExample)
PT (2) PT3125888T (enExample)
SG (1) SG11201608218QA (enExample)
SI (2) SI3125888T1 (enExample)
WO (1) WO2015150476A1 (enExample)
ZA (1) ZA201607286B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
NZ725492A (en) * 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MX379710B (es) * 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法
MX2020013181A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
HUE071482T2 (hu) 2018-06-06 2025-08-28 Minoryx Therapeutics S L (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
MX2020013182A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.
CN116390725A (zh) 2020-04-30 2023-07-04 米尼奥尔克斯治疗有限公司 用于治疗肺部炎症和间质性肺病的羟基吡格列酮
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
JP2026500743A (ja) 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ．エレ． レリグリタゾンの最適投薬
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100249988B1 (ko) * 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
WO1993022445A1 (en) * 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
ES2259736T3 (es) 2001-12-21 2006-10-16 Smithkline Beecham Corporation Regimen de dosificacion para activadores de ppar-gamma-.
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
AU2003254146A1 (en) * 2003-07-24 2005-03-07 Case Western Reserve University Methods for the treatment of parkinson's disease
EP2902026B1 (en) 2006-03-16 2017-10-04 Metabolic Solutions Development Company LLC Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
EP2512470B1 (en) * 2009-12-15 2016-11-30 Octeta Therapeutics, LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
NZ725492A (en) * 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical and pharmaceutical bulletin, 1995, 43(12), 2168-2172*

Also Published As

Publication number Publication date
US20160235729A1 (en) 2016-08-18
EP3388064B1 (en) 2021-03-10
EA201691997A1 (ru) 2017-02-28
AU2015239112B2 (en) 2020-05-07
NZ725492A (en) 2023-06-30
SG11201608218QA (en) 2016-10-28
SI3125888T1 (en) 2018-08-31
US9782395B2 (en) 2017-10-10
EP3125888A1 (en) 2017-02-08
MX2016012687A (es) 2017-04-27
ZA201607286B (en) 2021-07-28
CN106470991A (zh) 2017-03-01
PL3388064T3 (pl) 2021-07-19
SI3388064T1 (sl) 2021-08-31
PL3125888T3 (pl) 2018-09-28
LT3388064T (lt) 2021-05-25
HRP20180983T1 (hr) 2018-08-10
CA2943373A1 (en) 2015-10-08
US10179126B2 (en) 2019-01-15
HUE039555T2 (hu) 2019-01-28
CY1124088T1 (el) 2022-05-27
EP3388064A1 (en) 2018-10-17
US20180133202A1 (en) 2018-05-17
DK3388064T3 (da) 2021-04-19
CN106470991B (zh) 2020-07-31
US20190255032A1 (en) 2019-08-22
PT3388064T (pt) 2021-05-14
DK3125888T3 (en) 2018-06-25
EA202091120A3 (ru) 2020-12-30
JP2020117539A (ja) 2020-08-06
EP3125888B1 (en) 2018-05-23
PT3125888T (pt) 2018-07-20
MX373234B (es) 2020-05-08
CA2943373C (en) 2023-01-10
CY1120454T1 (el) 2019-07-10
CL2016002508A1 (es) 2017-04-21
HUE055351T2 (hu) 2022-05-28
JP6745726B2 (ja) 2020-08-26
IL248037A0 (en) 2016-11-30
EA202091120A2 (ru) 2020-08-31
KR20160145639A (ko) 2016-12-20
ES2872335T3 (es) 2021-11-02
LT3125888T (lt) 2018-07-10
ES2678046T3 (es) 2018-08-08
AU2015239112A1 (en) 2016-11-10
WO2015150476A1 (en) 2015-10-08
EA035866B1 (ru) 2020-08-21
JP2017511339A (ja) 2017-04-20
AU2015239112C1 (en) 2020-08-20
HRP20210518T1 (hr) 2021-05-14
BR112016022974A2 (pt) 2017-12-26
IL248037B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
EP3388064B1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
JP7510170B2 (ja) ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用
AU2022301208A1 (en) Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
CN113164490A (zh) 采用p2x3拮抗剂治疗瘙痒症
US20240010620A1 (en) Arylazabicyclo[2.1.1]hexylmethanols derivatives and medical uses thereof
JP2007532649A (ja) （４−アルキルピペラジニル）（フェニル）メタノン
HK1261676A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1261676B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MX2009001171A (es) Derivados de n-fenil-prenilamina para el tratamiento de enfermedades o desordenes cognitivos, neurodegenerativos o neuronales.
HK1233953B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233953A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233640A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233640B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
EA042526B1 (ru) Производные 2,4-тиазолидиндиона в лечении расстройств центральной нервной системы
US20070185168A1 (en) Piperidine derivatives
BR112016022974B1 (pt) Uso de um composto ou mistura dos compostos derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso central
EA047194B1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4